franckreporter/iStock via Getty Images
- Altimmune (ALT) -61% despite drug meeting main goal of reducing liver fat in trial.
- Vintage Wine Estates (VWE) -32% on Q4 earnings release.
- Comera Life Sciences (CMRA) -16%.
- Kaspien Holdings (KSPN) -14% on Q2 earnings release.
- NeuroBo Pharmaceuticals (NRBO) -8%.
- Infobird (IFBD) -9%.
- PaxMedica (PXMD) -8%.
- PolyPid (PYPD) -7%.
- Codiak BioSciences (CDAK) -6%.
- Phunware (PHUN) -6%.
- Block (SQ) -5%.
- Nucor (NUE) -5% after lower steel mills margins weigh heavy on Q3 earnings forecast sliding below consensus.
- HyreCar (HYRE) -5%.